Owens&Minor Investor Conference Presentation Deck

22 OMI-2021 Summary Highlights • Delivered on our 2021 guidance • Showed strong revenue growth ● ● Growth across the entire business led by Patient Direct, Global Products and Medical Distribution ● Both PPE and S&IP sales were up year-over-year • Our vertically-integrated business model allowed us to manage macro cost pressures • Continued to capture operating leverage through our investments in expanding manufacturing capacity, utilizing technology and strengthening infrastructure • Affirmed 2022 adj. EBITDA and adj. EPS guidance, and provided 2022 revenue guidance and modeling assumptions Please see Form 8-K filed by Owens & Minor, Inc. with the SEC on February 23, 2022 for additional financial information. Owens VI & Minor

View entire presentation